Literature DB >> 17040201

Novel therapies for rheumatoid arthritis.

Adriana H Tremoulet1, Salvatore Albani.   

Abstract

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that causes significant morbidity and mortality. The pathogenesis outlined to date in RA consists of a cascade of pro-inflammatory cytokines and chemokines leading to the recruitment of inflammatory cells and the self perpetuation of inflammation, ultimately leading to cartilage and bone destruction. The dramatic progress in understanding the molecular immunology in RA has led to a transition from conventional treatment with aggressive immune suppression to targeted biological-based therapies that control the inflammatory pathways associated with RA. This article reviews the current biological and small-molecule therapies approved for the treatment of RA and those in development, including antibodies, tolerising agents and vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17040201     DOI: 10.1517/13543784.15.11.1427

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  7 in total

1.  Increased expression of beta-arrestin 1 and 2 in murine models of rheumatoid arthritis: isoform specific regulation of inflammation.

Authors:  Pengfei Li; James A Cook; Gary S Gilkeson; Louis M Luttrell; Liping Wang; Keith T Borg; Perry V Halushka; Hongkuan Fan
Journal:  Mol Immunol       Date:  2011-08-19       Impact factor: 4.407

2.  Altered influenza virus haemagglutinin (HA)-derived peptide is potent therapy for CIA by inducing Th1 to Th2 shift.

Authors:  Jian Sun; Yuan Jia; Ru Li; Jianping Guo; Xiaolin Sun; Yanying Liu; Yingni Li; Haihong Yao; Xia Liu; Jing Zhao; Zhanguo Li
Journal:  Cell Mol Immunol       Date:  2011-03-07       Impact factor: 11.530

3.  Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses.

Authors:  Elena Gonzalez-Rey; Alejo Chorny; Raimundo G Del Moral; Nieves Varela; Mario Delgado
Journal:  Ann Rheum Dis       Date:  2006-12-06       Impact factor: 19.103

Review 4.  Manipulating B cell homeostasis: a key component in the advancement of targeted strategies.

Authors:  Laura S Treml; William J Quinn; John F Treml; Jean L Scholz; Michael P Cancro
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

5.  Osteoarticular Expression of Musashi-1 in an Experimental Model of Arthritis.

Authors:  Francisco O'Valle; Magdalena Peregrina; Vicente Crespo-Lora; Pablo Galindo-Moreno; Maria Roman; Miguel Padial-Molina; Francisco Mesa; Jose Aneiros-Fernandez; David Aguilar; Elena Gonzalez-Rey; Mario Delgado; Pedro Hernandez-Cortes
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

6.  Induction of apoptosis of human primary osteoclasts treated with extracts from the medicinal plant Emblica officinalis.

Authors:  Letizia Penolazzi; Ilaria Lampronti; Monica Borgatti; Mahmud Tareq Hassan Khan; Margherita Zennaro; Roberta Piva; Roberto Gambari
Journal:  BMC Complement Altern Med       Date:  2008-10-30       Impact factor: 3.659

7.  Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response.

Authors:  Elena Gonzalez-Rey; Ruben Martínez-Romero; Francisco O'Valle; Rocío Aguilar-Quesada; Carmen Conde; Mario Delgado; F Javier Oliver
Journal:  PLoS One       Date:  2007-10-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.